Skip to Content
Merck
  • Long-term loss of osteoclasts and unopposed cortical mineral apposition following limited field irradiation.

Long-term loss of osteoclasts and unopposed cortical mineral apposition following limited field irradiation.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society (2014-11-20)
Megan E Oest, Veerle Franken, Timothy Kuchera, Judy Strauss, Timothy A Damron
ABSTRACT

Late-onset fragility fractures are a common complication following radiotherapy for metastatic disease and soft tissue sarcomas. Using a murine hindlimb focal irradiation model (RTx), we quantified time-dependent changes in osteoclasts and mineral apposition rate (MAR). Mice received either a single, unilateral 5 Gy exposure or four fractionated doses (4 × 5 Gy). Osteoclast numbers and MAR were evaluated histologically at 1, 2, 4, 8, 12, and 26 weeks post-RTx. Radiation induced an early, transient increase in osteoclasts followed by long-term depletion. Increased osteoclast numbers correlated temporally with trabecular resorption; the resorbed trabeculae were not later restored. Radiotherapy did not attenuate MAR at any time point. A transient, early increase in MAR was noted in both RTx groups, however, the 4 × 5 Gy group exhibited an unexpected spike in MAR eight weeks. Persistent depletion of osteoclasts permitted anabolic activity to continue unopposed, resulting in cortical thickening. These biological responses likely contribute to post-radiotherapy bone fragility via microdamage accumulation and matrix embrittlement in the absence of osteoclastic remodeling, and trabecular resorption-induced decrease in bone strength. The temporal distribution of osteoclast numbers suggests that anti-resorptive therapies may be of clinical benefit only if started prior to radiotherapy and continued through the following period of increased osteoclastic remodeling.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methyl methacrylate, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
Luperox® A75FP, Benzoyl peroxide, 75% remainder water, contains 25 wt. % water as stabilizer, 75%
Sigma-Aldrich
Luperox® A75, Benzoyl peroxide, 75%, remainder water
Sigma-Aldrich
Benzoyl peroxide blend with dicyclohexyl phthalate, suitable for use as a catalyst for electron microscopy. Modified to render it safe in transit.
Sigma-Aldrich
Methyl methacrylate, 99%, stabilized
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Methyl methacrylate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Butyl methacrylate, 99%, contains monomethyl ether hydroquinone as inhibitor
Sigma-Aldrich
Methyl benzoate, 99%
Supelco
Methyl benzoate, analytical standard
Sigma-Aldrich
Methyl benzoate, ≥98%, FCC, FG
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Sigma-Aldrich
Methyl benzoate, natural, ≥98%, FCC, FG
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Butyl methacrylate, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland